0.57
-0.2554(-30.77%)
Currency In USD
| Previous Close | 0.83 |
| Open | 0.78 |
| Day High | 0.83 |
| Day Low | 0.56 |
| 52-Week High | 5.39 |
| 52-Week Low | 0.33 |
| Volume | 480,683 |
| Average Volume | 504,100 |
| Market Cap | 7.05M |
| PE | -0.35 |
| EPS | -1.64 |
| Moving Average 50 Days | 0.65 |
| Moving Average 200 Days | 1.12 |
| Change | -0.26 |
If you invested $1000 in Kineta, Inc. (KA) since IPO date, it would be worth $2.54 as of December 24, 2025 at a share price of $0.575. Whereas If you bought $1000 worth of Kineta, Inc. (KA) shares 5 years ago, it would be worth $17.14 as of December 24, 2025 at a share price of $0.575.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
GlobeNewswire Inc.
Oct 08, 2024 1:00 PM GMT
Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrol
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
GlobeNewswire Inc.
Oct 04, 2024 1:05 PM GMT
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstra
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
GlobeNewswire Inc.
Oct 02, 2024 8:05 PM GMT
TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer SEATTLE, Oct. 02, 20